Goldman Sachs questions whether curing patients is a sustainable business model

Re:Goldman Sachs questions whether curing patients is a sust... by PeterStuer on Friday April 13, 2018 @09:10AM (#16829616)

Well, we certainly have exponentially more consumption of treatments for depression, allergies, obesity, pain, attention disorders, ... . That these are very lucrative for the companies supplying them (under a state-covered monopoly agreement) is also correct. Whether those constitute 'cures' is highly debatable.

[ Parent | on HN ]

Re:Goldman Sachs questions whether curing patients is a sust... by refurb on Friday April 13, 2018 @11:22AM (#16830806)

We now have a cure for HCV, relapsing blood cancers, genetic forms of blindness, blood clotting disorders (in a year or two). I can give you more examples if you have trouble finding them.

And yes, the companies are giving a monopoly on one drug which allows competitors to create others similar to it. And the patent only gives about a decade of monopoly, after which the price drops to ~10% of what it was.

[ Parent | on HN ]